Atea Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Atea Pharmaceuticals, Inc. (AVIR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.38M, a 27.56% decline year-over-year.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.73M, a 46.35% decline year-over-year.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.52M, a 62.87% decline year-over-year.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.67M, a 63.31% decline year-over-year.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $20.72M, a 59.97% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $51.77M, a 4.73% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $49.43M, a 5.80% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $46.72M, a 17.91% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.38M 10-Q · filed 2026-08-12 | $7.11M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $3.73M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $20.72M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $4.52M 10-Q · filed 2025-11-12 | $9.18M derived: sum of 2 quarters · filed 2026-08-12 | $16.14M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $4.67M 10-Q · filed 2026-08-12 | $11.62M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $6.95M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $51.77M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $12.16M 10-Q · filed 2025-11-12 | $24.88M derived: sum of 2 quarters · filed 2025-11-12 | $37.47M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $12.72M 10-Q · filed 2025-11-12 | $25.31M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $12.59M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $49.43M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $12.38M 10-Q · filed 2024-11-07 | $24.74M derived: sum of 2 quarters · filed 2024-11-07 | $37.27M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $12.35M 10-Q · filed 2024-11-07 | $24.89M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $12.54M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $46.72M 10-K · filed 2024-02-28 | |||
| 2022-09-30 | $11.50M 10-Q · filed 2023-11-08 | $23.41M derived: sum of 2 quarters · filed 2023-11-08 | $35.07M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $11.91M 10-Q · filed 2023-11-08 | $23.57M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $11.66M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $39.62M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $10.99M 10-Q · filed 2022-11-07 | $21.00M derived: sum of 2 quarters · filed 2022-11-07 | $28.27M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $10.01M 10-Q · filed 2022-11-07 | $17.28M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $7.27M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $6.80M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $4.24M 10-Q · filed 2021-11-12 | $4.45M derived: sum of 2 quarters · filed 2021-11-12 | $4.64M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $209.00K 10-Q · filed 2021-11-12 | $398.00K derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $189.00K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $624.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $157.00K 10-Q · filed 2020-12-10 | $304.00K derived: sum of 2 quarters · filed 2020-12-10 | $450.00K derived: sum of 3 quarters · filed 2020-12-10 | |
| 2019-06-30 | $147.00K 10-Q · filed 2020-12-10 | $293.00K derived: sum of 2 quarters · filed 2020-12-10 | ||
| 2019-03-31 | $146.00K 10-Q · filed 2020-12-10 | |||
| 2018-12-31 | $414.00K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |